ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
-0.10%
US Dollar vs MXN
16.6733
-0.04%
Brent Oil
83.385
0.22%
Bitcoin
66,140.57
1.38%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. Oragenics Inc (OGEN)

  7. Oragenics Inc (OGEN) Noticias

OGEN Oragenics Inc

1.64
0.00 (0.00%)
16 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Oragenics Inc OGEN AMEX Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 1.64 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.64
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/5/202407:00EDGAR2Form 8-K - Current report
16/5/202407:00GLOBEOragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002,..
15/5/202412:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202407:14EDGAR2Form 8-K - Current report
07/5/202407:00GLOBEOragenics Partners with Avance Clinical for Phase II..
19/4/202416:50BWOragenics, Inc. Announces Notification of Noncompliance with..
01/4/202408:05BWOragenics, Inc. Files 10K and Provides Company Update
18/3/202406:00BWOragenics Appoints James Kelly MD, Chief Medical Officer, to..
06/3/202415:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/3/202406:45BWOragenics, Inc. Prepares Drug for Phase II Clinical Trials..
01/3/202415:04BWOragenics Announces Closing of Public Offering
29/2/202415:41EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202408:03EDGAR2Form 8-K - Current report
27/2/202420:25BWOragenics Announces Pricing of Public Offering
27/2/202416:09EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
27/2/202416:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/2/202415:33BWOragenics Announces Proposed Public Offering
12/2/202419:06EDGAR2Form SC 13D - General statement of acquisition of beneficial..
12/2/202415:45EDGAR2Form 8-K - Current report
12/2/202415:41BWOragenics, Inc. Announces Leadership Transition
07/2/202407:00EDGAR2Form 8-K - Current report
07/2/202407:00BWOragenics, Inc. Announces Expiration of Its Investment..
05/2/202407:00EDGAR2Form 8-K - Current report
05/2/202407:00BWOragenics, Inc. Preparing for Phase II Clinical Trials to..
23/1/202416:34BWOragenics Announces Termination of At-The-Market Offering..
23/1/202416:18EDGAR2Form 8-K - Current report
22/1/202416:30EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
16/1/202408:10EDGAR2Form 8-K - Current report
16/1/202408:08EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
16/1/202408:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/1/202415:37EDGAR2Form S-8 - Securities to be offered to employees in employee..
02/1/202416:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202408:22EDGAR2Form 8-K - Current report
02/1/202406:30BWOragenics Completes Acquisition of Odyssey Health’s..
29/12/202306:30EDGAR2Form 8-K - Current report
15/12/202314:45EDGAR2Form 8-K - Current report
08/12/202315:00EDGAR2Form 8-K - Current report
01/12/202316:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202316:50EDGAR2Form 144 - Report of proposed sale of securities
20/11/202314:45EDGAR2Form 8-K - Current report
16/11/202313:37EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
02/11/202306:00EDGAR2Form 8-K - Current report
02/11/202306:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
02/11/202306:00BWOragenics Issues Update to Shareholders
30/10/202315:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/10/202315:00EDGAR2Form DEF 14A - Other definitive proxy statements
18/10/202307:30BWOragenics Announces Appointment of Bruce Cassidy and John..
06/10/202315:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202315:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202315:28EDGAR2Form 3 - Initial statement of beneficial ownership of..

Su Consulta Reciente

AMEX
OGEN
Oragenics
LSE
0QQ7
Meyer Burger Technology
LSE
0OA4
Vusiongroup
LSE
MFX
Manx Financial
NYSE
TDG
Transdigm
AMEX
PRK
Park National
LSE
LFI
London Finance & Investm...
LSE
0JSG
Euro Ressources
NASDAQ
UFCS
United Fire
LSE
0NT5
Fourlis
AMEX
AMV
Amerivest
LSE
EDV
Endeavour Mining
NYSE
GR
Goodrich
LSE
0GUT
Openlimit
EU
SHELL
Shell
AMEX
MPQ
Meredith Enterprises
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados